Anaplastic Thyroid Cancer Drugs Market to record USD 230.53 Mn growth; Akorn Inc., Amneal Pharmaceuticals Inc., Bayer AG identified as key vendors – Technavio – Yahoo Finance
NEW YORK, Nov. 9, 2022 /PRNewswire/ — The “Anaplastic Thyroid Cancer Drugs Market by Product and Geography – Forecast and Analysis 2022-2026” report has been added to Technavio’s offering. The report expects the market size to grow by USD 230.53 million, accelerating at a CAGR of 5.44% during the forecast period. The global anaplastic thyroid cancer drugs market is fragmented with more than 20 companies and various types of branded drugs and generics of some chemotherapeutics. The competition is high among vendors owing to the introduction of novel therapies in the market. Also, the presence of a strong pipeline of drugs used for treating anaplastic thyroid cancer will further intensify the competition during the forecast period. Furthermore, the market will witness the approvals of some drugs during the forecast period, which will intensify the competition among vendors. Get deeper insights into the vendor landscape and make informed decisions. Buy Report Now!
Anaplastic Thyroid Cancer Drugs Market 2022-2026: Segmentation
With a focus on identifying dominant industry influencers, Technavio’s reports present a detailed study by the way of synthesis, and summation of data from multiple sources. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment.
The report also covers the following areas:
Anaplastic Thyroid Cancer Drugs Market Size
Anaplastic Thyroid Cancer Drugs Market Trends
Anaplastic Thyroid Cancer Drugs Market Industry Analysis
Anaplastic Thyroid Cancer Drugs Market 2022-2026: Segmentation
The market growth will be significant in the chemotherapy segment during the forecast period. The growth of the chemotherapy segment can be mainly attributed to the high prevalence of thyroid cancer and chemotherapy being the second-line treatment for anaplastic thyroid cancer after surgery. The incidence rate of thyroid cancer is increasing at a significant rate, almost increasing threefold every ten years. Although the majority of thyroid tumors are curable, about 2%-3% of thyroid cancers are refractory to standard treatments. These types include undifferentiated, highly aggressive, and mostly chemo-resistant tumors and are known as anaplastic thyroid cancer.
37% of the market growth will come from North America during the forecast period. The market growth in North America is primarily attributed to the increased cases of thyroid cancer in the region. The increasing geriatric population in the region is another factor propelling the growth of the anaplastic thyroid cancer drugs market in North America.
Identify other potential segments and regions in the market. Download Free Sample Report
Anaplastic Thyroid Cancer Drugs Market 2022-2026: Vendor Analysis and Scope
Some of the major vendors of the anaplastic thyroid cancer drugs market in l4 industry include Akorn Inc., Amneal Pharmaceuticals Inc., Bayer AG, Bristol Myers Squibb Co., Cipla Ltd., Daiichi Sankyo Co. Ltd., Dr. Reddys Laboratories Ltd., Eisai Co. Ltd., Exelixis Inc., Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson, Medtronic Plc, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and Viatris Inc.
To help businesses improve their market position, Technavio’s report provides a detailed analysis of around 25 vendors operating in the market. Backed with competitive intelligence and benchmarking, our research report on the anaplastic thyroid cancer drugs market is designed to provide entry support, customer profile, & M&As as well as go-to-market strategy support.
The High prevalence of thyroid cancer, the introduction of targeted therapies, and the rising geriatric population will offer immense growth opportunities. To leverage the current opportunities, market vendors must strengthen their foothold in the fast-growing segments while maintaining their positions in the slow-growing segments.
Technavio’s library includes over 17,000+ reports covering more than 2,000 emerging technologies. Subscribe to our “Basic Plan” at just USD 5,000 and get lifetime access to our Technavio Insights
Anaplastic Thyroid Cancer Drugs Market 2022-2026: Key Highlights
CAGR of the market during the forecast period 2022-2026
Detailed information on factors that will assist anaplastic thyroid cancer drugs market growth during the next five years
Estimation of the anaplastic thyroid cancer drugs market size and its contribution to the parent market
Predictions on upcoming trends and changes in consumer behavior
The growth of the anaplastic thyroid cancer drugs market
Analysis of the market’s competitive landscape and detailed information on vendors
Comprehensive details of factors that will challenge the growth of anaplastic thyroid cancer drugs market vendors
The BRAF kinase inhibitors market share is expected to accelerate at a CAGR of 7.73%, and reach an estimated value of USD 1.19 billion by 2026. The high target affinity and specificity of BRAF kinase inhibitors is notably driving the BRAF kinase inhibitors market growth, although factors such as the availability of substitute therapies may impede the market growth.
The cancer biologics market share is expected to increase by USD 34.97 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 8.91%. The rising global incidence of cancer is notably driving the cancer biologics market growth, although factors such as the high cost of cancer biologics may impede market growth.
Anaplastic Thyroid Cancer Drugs Market Scope
Growth momentum & CAGR
Accelerate at a CAGR of 5.44%
Market growth 2022-2026
USD 230.53 million
YoY growth (%)
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution
North America at 37%
Key consumer countries
US, Canada, Italy, China, and India
Leading companies, competitive strategies, consumer engagement scope
Akorn Inc., Amneal Pharmaceuticals Inc., Bayer AG, Bristol Myers Squibb Co., Cipla Ltd., Daiichi Sankyo Co. Ltd., Dr. Reddys Laboratories Ltd., Eisai Co. Ltd., Exelixis Inc., Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson, Medtronic Plc, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and Viatris Inc.
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Table of contents:
1 Executive Summary
1.1 Market overview
2 Market Landscape
2.1 Market ecosystem
3 Market Sizing
3.1 Market definition
3.2 Market segment analysis
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
4 Five Forces Analysis
4.1 Five forces summary
4.2 Bargaining power of buyers
4.3 Bargaining power of suppliers
4.4 Threat of new entrants
4.5 Threat of substitutes
4.6 Threat of rivalry
4.7 Market condition
5 Market Segmentation by Product
5.1 Market segments
5.2 Comparison by Product
5.3 Chemotherapy – Market size and forecast 2021-2026
5.4 Novel therapy – Market size and forecast 2021-2026
5.5 Market opportunity by Product
6 Customer Landscape
6.1 Customer landscape overview
7 Geographic Landscape
7.1 Geographic segmentation
7.2 Geographic comparison
7.3 North America – Market size and forecast 2021-2026
7.4 Europe – Market size and forecast 2021-2026
7.5 Asia – Market size and forecast 2021-2026
7.6 Rest of World (ROW) – Market size and forecast 2021-2026
7.7 US – Market size and forecast 2021-2026
7.8 Italy – Market size and forecast 2021-2026
7.9 China – Market size and forecast 2021-2026
7.10 Canada – Market size and forecast 2021-2026
7.11 India – Market size and forecast 2021-2026
7.12 Market opportunity by geography
8 Drivers, Challenges, and Trends
8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
8.4 Market trends
9 Vendor Landscape
9.2 Vendor landscape
9.3 Landscape disruption
9.4 Industry risks
10 Vendor Analysis
10.1 Vendors covered
10.2 Market positioning of vendors
10.3 Bayer AG
10.4 Bristol Myers Squibb Co.
10.5 Eisai Co. Ltd.
10.6 Johnson and Johnson
10.7 Medtronic Plc
10.8 Merck KGaA
10.9 Novartis AG
10.10 Pfizer Inc.
10.11 Takeda Pharmaceutical Co. Ltd.
10.12 Viatris Inc.
11.1 Scope of the report
11.2 Inclusions and exclusions checklist
11.3 Currency conversion rates for US$
11.4 Research methodology
11.5 List of abbreviations
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
View original content to download multimedia:https://www.prnewswire.com/news-releases/anaplastic-thyroid-cancer-drugs-market-to-record-usd-230-53-mn-growth-akorn-inc-amneal-pharmaceuticals-inc-bayer-ag-identified-as-key-vendors—technavio-301671305.html
Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services
A problem with a vendor in the supply chain of Wichita-based Spirit AeroSystems Inc. slowed delivery activity for the Boeing Co. last month. Boeing this week reported 35 aircraft deliveries for October, down from 51 deliveries in September as handovers of its 737 MAX jet fell from 36 to 22 sequentially. The slip comes as Boeing works to stabilize production of its best-selling MAX at 31 aircraft per month, with commercial airplanes unit CEO Stan Deal attributing the decline at the company’s investor day last week to a problem with its fuselage supplier.
BYD, BMW and XPeng have been highlighted in this Industry Outlook article.
U.S. aerospace giant Raytheon Technologies Corp said on Tuesday stability in supply of castings, used in making engines, may only happen well into next year after a strong recovery in aftermarket sales put further pressure on a battered supply chain. "I think we expect that (castings supply) to take the rest of this year and into probably through most of next year to stabilize and get back kind of to the levels where we need to see it," Raytheon finance chief Neil Mitchill said. Raytheon, a supplier to planemakers Boeing Co and Airbus SE, is working with vendors to find alternative ways to test and qualify materials and help them get parts out of their doors faster, Mitchill said at a Baird conference.
Shell has been handed £90m of taxpayer cash under the Government’s scheme to help families with surging energy bills.
Third-quarter filings with the SEC indicate Boeing is prepared to pull the plug on the jets without a needed certification extension.
That’s a big problem. Copper mines take 15 years to begin producing the metal necessary for renewable energy initiatives.
Eunice Shin, Prophet Global Leader for Tech, Media & Entertainment Practice, and Direct-to-Consumer Practice, joins Yahoo Finance Live to discuss Disney earnings, advertising demand, and headwinds for streaming companies.
FISSION URANIUM CORP. ("Fission" or the "Company") is pleased to announce that it has entered into an Engagement and Capacity Agreement (the "Agreement") with the Birch Narrows Dene Nation ("BNDN"). Fission's PLS project (the "Project") in the southwest Athabasca Basin region is within the BNDN's Ancestral Lands. Fission commenced an Environmental Assessment in December 2021 and expects to complete a Feasibility Study by the end of 2022.
Most people don't pay attention to diesel fuel prices, but they're up way more than the cost of gasoline and driving the cost of many other things higher.
Peabody's 3rd-quarter earnings report shows incredible strength
Indian Oil Corp has offered one diesel cargo to be loaded in early December, its first export in almost three months, three sources who reviewed the tender document said on Thursday. "The availability could be because of supply resumption after the end of a turnaround at one of the company's Paradip refinery in mid- to second half September," one of the sources said. The tender to sell up to 16,460 tonnes of diesel loading from Paradip will close on Nov. 11, with bids to remain valid until the close of the same day.
Oil futures continued to slide on Thursday as concerns about Chinese demand and rising inventories weighed on prices
Toronto, Ontario – November 9, 2022 – Noble Mineral Exploration Inc. (“Noble” or the “Company”) (TSXV:NOB), (FRANKFURT:NB7), (OTCQB:NLPXF) is pleased to report on progress for a number of its activ…
The biggest banks will push through the economic headwinds just fine, but the biggest of the big will come out of it stronger than ever.
Cotton contracts for December fell 1.5 cent, or 1.7%, to 86.18 cents per lb at 1310 ET (1810 GMT) having shed as much as 4% at 84.19 cents a lb after USDA's monthly World Agricultural and Supply Demand Estimates (WASDE) report. "All in all, this report is trying to show the current reality of the market, both on the supply and the demand side, with the latter being the one that could come back at any point, unlike production," said Valentin Olah, cotton risk management consultant at StoneX Group. The USDA report saw U.S. ending stocks 200,000 bales higher at 3 million bales, which Olah said was surprising and "softens a bit the tightness of ending stocks, for now."
Biden has imposed policies that reveal little sensitivity to how the American energy markets work, forcing gasoline prices to rise as supplies are squeezed.
They are the corporate chiefs whose actions, work and opinions are reverberating through these financial markets. There are 14 CEOs on the MarketWatch 50.
Higher oil-equivalent production and prices aid Viper Energy's (VNOM) Q3 earnings.
BRUSSELS (Reuters) -ArcelorMittal, the world’s second-largest steelmaker, reported higher-than-expected third-quarter earnings on Thursday as cost cutting and energy savings offset declining demand. ArcelorMittal said it had cut its gas consumption in Europe by 30% in a bid to counter surging energy prices, as a slowdown in economic growth across the globe weakened demand for steel.